|
1
|
Freeman C, Berg JW and Cutler SJ:
Occurrence and prognosis of extranodal lymphomas. Cancer.
29:252–260. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berglund M, Hedström G, Amini RM, Enblad G
and Thunberg U: High expression of microRNA-200c predicts poor
clinical outcome in diffuse large B-cell lymphoma. Oncol Rep.
29:720–724. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Papaxoinis G, Papageorgiou S, Rontogianni
D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C,
Xiros N and Economopoulos T: Primary gastrointestinal non-Hodgkin's
lymphoma: A clinicopathologic study of 128 cases in Greece. A
Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma.
47:2140–2146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herrmann R, Panahon AM, Barcos MP, Walsh D
and Stutzman L: Gastrointestinal involvement in non-Hodgkin's
lymphoma. Cancer. 46:215–222. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Müller AM, Ihorst G, Mertelsmann R and
Engelhardt M: Epidemiology of non-Hodgkin's lymphoma (NHL): Trends,
geographic distribution, and etiology. Ann Hematol. 84:1–12. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Malipatel R, Patil M, Pritilata Rout P,
Correa M and Devarbhavi H: Primary gastric lymphoma:
Clinicopathological profile. Euroasian J Hepatogastroenterol.
8:6–10. 2018.PubMed/NCBI
|
|
7
|
Xia B, Zhang L, Guo SQ, Li XW, Qu FL, Zhao
HF, Zhang LY, Sun BC, You J and Zhang YZ: Coexpression of MYC and
BCL-2 predicts prognosis in primary gastrointestinal diffuse large
B-cell lymphoma. World J Gastroenterol. 21:2433–2442. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peng JC, Zhong L and Ran ZH: Primary
lymphomas in the gastrointestinal tract. J Dig Dis. 16:169–176.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao H, Zhang L, Guo S, Yuan T, Xia B, Qu
F, Zhang L and Zhang Y: Downregulated expression of Dicer1 predicts
inferior survival in primary gastrointestinal diffuse large B-cell
lymphoma treated with CHOP-like regimen and rituximab. Med Oncol.
31:2062014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Treiber T, Treiber N and Meister G:
Regulation of microRNA biogenesis and function. Thromb Haemost.
107:605–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Lu P, Wang DD, Yang SJ, Wu Y, Shen
HY, Zhong SL, Zhao JH and Tang JH: The role of miRNAs in drug
resistance and prognosis of breast cancer formalin-fixed
paraffin-embedded tissues. Gene. 595:221–226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang D, Qiu C, Zhang H, Wang J, Cui Q and
Yin Y: Human microRNA oncogenes and tumor suppressors show
significantly different biological patterns: from functions to
targets. PLoS One. 5:e130672010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiong J, Wei B, Ye Q and Liu W:
MiR-30a-5p/UBE3C axis regulates breast cancer cell proliferation
and migration. Biochem Biophys Res Commun. 516:1013–1018. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et
al: A MicroRNA signature associated with prognosis and progression
in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lawrie CH, Gal S, Dunlop HM, Pushkaran B,
Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J,
Wainscoat JS, et al: Detection of elevated levels of
tumour-associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang HD, Jiang LH, Sun DW, Li J and Ji
ZL: The role of miR-130a in cancer. Breast Cancer. 24:521–527.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang H, Yu WW, Wang LL and Peng Y:
miR-130a acts as a potential diagnostic biomarker and promotes
gastric cancer migration, invasion and proliferation by targeting
RUNX3. Oncol Rep. 34:1153–1161. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ,
Wang TY, Li HC and Wu XN: Differential expression of miRNAs in
esophageal cancer tissue. Oncol Lett. 5:1639–1642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishihara K, Sasaki D, Tsuruda K, Inokuchi
N, Nagai K, Hasegawa H, Yanagihara K and Kamihira S: Impact of
miR-155 and miR-126 as novel biomarkers on the assessment of
disease progression and prognosis in adult T-cell leukemia. Cancer
Epidemiol. 36:560–565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ding C, Chen SN, Macleod RAF, Drexler HG,
Nagel S, Wu DP, Sun AN and Dai HP: MiR-130a is aberrantly
overexpressed in adult acute myeloid leukemia with t(8;21) and its
suppression induces AML cell death. Ups J Med Sci. 123:19–27. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan WX, Gui YX, Na WN, Chao J and Yang X:
Circulating microRNA-125b and microRNA-130a expression profiles
predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma
patients. Oncol Lett. 11:423–432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li B, Huang P, Qiu J, Liao Y, Hong J and
Yuan Y: MicroRNA-130a is down-regulated in hepatocellular carcinoma
and associates with poor prognosis. Med Oncol. 31:2302014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kovaleva V, Mora R, Park YJ, Plass C,
Chiramel AI, Bartenschlager R, Döhner H, Stilgenbauer S, Pscherer
A, Lichter P and Seiffert M: miRNA-130a targets ATG2B and DICER1 to
inhibit autophagy and trigger killing of chronic lymphocytic
leukemia cells. Cancer Res. 72:1763–1772. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Borges NM, do Vale Elias M, Fook-Alves VL,
Andrade TA, de Conti ML, Macedo MP, Begnami MD, Campos AH, Etto LY,
Bortoluzzo AB, et al: Angiomirs expression profiling in diffuse
large B-Cell lymphoma. Oncotarget. 7:4806–4816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tomonaga M: Outline and direction of
revised WHO classification of tumors of haematopoietic and lymphoid
tissues. Rinsho Ketsueki. 50:1401–1406. 2009.PubMed/NCBI
|
|
27
|
Rohatiner A, d'Amore F, Coiffier B,
Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem
P, Shipp M, et al: Report on a workshop convened to discuss the
pathological and staging classifications of gastrointestinal tract
lymphoma. Ann. Oncol. 5:397–400. 1994.
|
|
28
|
Sok M, Zavrl M, Greif B and Srpčič M:
Objective assessment of WHO/ECOG performance status. Support Care
Cancer. 27:3793–3798. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ghimire P, Wu GY and Zhu L: Primary
gastrointestinal lymphoma. World J. Gastroenterol. 17:697–707.
2011.
|
|
30
|
Chen F, Liu S, Zhou Y, Shen H and Zuo X:
Mad2 overexpression is associated with high cell proliferation and
reduced disease-free survival in primary gastrointestinal diffuse
large B-cell lymphoma. Hematology. 21:399–403. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Muris JJ, Meijer CJ, Vos W, van Krieken
JH, Jiwa NM, Ossenkoppele GJ and Oudejans JJ: Immunohistochemical
profiling based on Bcl-2, CD10 and MUM1 expression improves risk
stratification in patients with primary nodal diffuse large B cell
lymphoma. J Pathol. 208:714–723. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Horn H, Ziepert M, Becher C, Barth TF,
Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, et
al: MYC status in concert with BCL2 and BCL6 expression predicts
outcome in diffuse large B-cell lymphoma. Blood. 121:2253–2263.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Juarez-Salcedo LM, Sokol L, Chavez JC and
Dalia S: Primary gastric lymphoma, epidemiology, clinical
diagnosis, and treatment. Cancer Control. 25:1–12. 2018. View Article : Google Scholar
|
|
36
|
Ahmadvand M, Eskandari M, Pashaiefar H,
Yaghmaie M, Manoochehrabadi S, Khakpour G, Sheikhsaran F and
Montazer Zohour M: Over expression of circulating miR-155 predicts
prognosis in diffuse large B-cell lymphoma. Leuk Res. 70:45–48.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Craig VJ, Tzankov A, Flori M, Schmid CA,
Bader AG and Muller A: Systemic microRNA-34a delivery induces
apoptosis and abrogates growth of diffuse large B-cell lymphoma in
vivo. Leukemia. 26:2421–2424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Craig VJ, Cogliatti SB, Imig J, Renner C,
Neuenschwander S, Rehrauer H, Schlapbach R, Dirnhofer S, Tzankov A
and Müller A: Myc-mediated repression of microRNA-34a promotes
high-grade transformation of B-cell lymphoma by dysregulation of
FoxP1. Blood. 117:6227–6236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang F, Miao L, Mei Y and Wu M: Retinoic
acid-induced HOXA5 expression is co-regulated by HuR and miR-130a.
Cell Signal. 25:1476–1485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou YM, Liu J and Sun W: MiR-130a
overcomes gefitinib resistance by targeting met in non-small cell
lung cancer cell lines. Asian Pac. J Cancer Prev. 15:1391–1406.
2014.
|
|
41
|
Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q
and Zhang J: Upregulated miR-130a increases drug resistance by
regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.
Biochem Biophys Res Commun. 425:468–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu X and Li Z: New insights into MicroRNAs
involves in drug resistance in diffuse large B cell lymphoma. Am J
Transl Res. 7:2536–2542. 2015.PubMed/NCBI
|
|
43
|
Kawamoto K, Miyoshi H, Yoshida N, Nakamura
N, Ohshima K, Sone H and Takizawa J: MYC translocation and/or BCL 2
protein expression are associated with poor prognosis in diffuse
large B-cell lymphoma. Cancer Sci. 107:853–861. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Plati J, Bucur O and Khosravi-Far R:
Apoptotic cell signaling in cancer progression and therapy. Integr
Biol. 3:279–96. 2011. View Article : Google Scholar
|
|
45
|
Hu S, Xu-Monette ZY, Tzankov A, Green T,
Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, et al:
MYC/BCL2 protein coexpression contributes to the inferior survival
of activated B-cell subtype of diffuse large B-cell lymphoma and
demonstrates high-risk gene expression signatures: A report from
The International DLBCL Rituximab-CHOP consortium program. Blood.
121:4021–4031. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lim KH, Yang Y and Staudt LM: Pathogenetic
importance and therapeutic implications of NF-kB in lymphoid
malignancies. Immunol Rev. 246:359–378. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Feng Y, Zhou S, Li G, Hu C, Zou W, Zhang H
and Sun L: Nuclear factor-κB-dependent microRNA-130a upregulation
promotes cervical cancer cell growth by targeting phosphatase and
tensin homolog. Arch Biochem Biophys. 598:57–65. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang Y, Zhang X, Tang W, Lin Z, Xu L, Dong
R, Li Y, Li J, Zhang Z, Li X, et al: miR-130a upregulates mTOR
pathway by targeting TSC1 and is transactivated by NF-κB in
high-grade serous ovarian carcinoma. Cell Death Differ.
24:2089–2100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Filip D and Mraz M: The role of MYC in the
transformation and aggressiveness of ‘indolent’ B-cell
malignancies. Leuk. Lymphoma. 61:510–524. 2019. View Article : Google Scholar
|
|
50
|
Zhu J, Zheng X and Yang X: Diagnostic and
mechanistic values of microRNA-130a and microRNA-203 in patients
with papillary thyroid carcinoma. J Cell Biochem. 121:3657–3666.
2020. View Article : Google Scholar
|
|
51
|
Nguyen L, Papenhausen P and Shao H: The
Role of c-MYC in B-cell lymphomas: Diagnostic and molecular
aspects. Genes (Basel). 8:1162017. View Article : Google Scholar
|
|
52
|
Johnson NA, Slack GW, Savage KJ, Connors
JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, et
al: Concurrent expression of MYC and BCL2 in diffuse large B-cell
lymphoma treated with rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone. J Clin Oncol. 30:3452–3459. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lee SH, Jung YD, Choi YS and Lee YM:
Targeting of RUNX3 by miR-130a and miR-495 cooperatively increases
cell proliferation and tumor angiogenesis in gastric cancer cells.
Oncotarget. 6:33269–33278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang XC, Tian LL, Wu HL, Jiang XY, Du LQ,
Zhang H, Wang YY, Wu HY, Li DG, She Y, et al: Expression of
miRNA-130a in nonsmall cell lung cancer. Am J Med Sci. 340:385–388.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhao H, Zhang LE, Guo S, Yuan T, Xia B,
Zhang L and Zhang Y: Overexpression of DNA methyltransferase 1 as a
negative independent prognostic factor in primary gastrointestinal
diffuse large B-cell lymphoma treated with CHOP-like regimen and
rituximab. Oncol Lett. 9:2307–2312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pallasch CP, Patz M, Park YJ, Hagist S,
Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J,
et al: miRNA deregulation by epigenetic silencing disrupts
suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.
Blood. 114:3255–3264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kanagal-Shamanna R: Digital PCR:
Principles and Applications. Methods Mol Biol. 1392:43–50. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cao L, Cui X, Hu J, Li Z, Choi JR, Yang Q,
Lin M, Ying Hui L and Xu F: Advances in digital polymerase chain
reaction (dPCR) and its emerging biomedical applications. Biosens
Bioelectron. 90:459–474. 2017. View Article : Google Scholar : PubMed/NCBI
|
